Advertisement
Singapore markets closed

  • Straits Times Index

    3,307.90
    -6.15 (-0.19%)
     

  • Nikkei

    38,617.10
    -329.83 (-0.85%)
     

  • Hang Seng

    19,195.60
    -25.02 (-0.13%)
     

  • FTSE 100

    8,394.01
    -22.44 (-0.27%)
     

  • Bitcoin USD

    70,085.17
    -786.36 (-1.11%)
     

  • CMC Crypto 200

    1,471.39
    -55.03 (-3.61%)
     

  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     

  • Dow

    39,872.99
    +66.22 (+0.17%)
     

  • Nasdaq

    16,832.62
    +37.75 (+0.22%)
     

  • Gold

    2,414.80
    -11.10 (-0.46%)
     

  • Crude Oil

    77.50
    -1.16 (-1.47%)
     

  • 10-Yr Bond

    4.4140
    -0.0230 (-0.52%)
     

  • FTSE Bursa Malaysia

    1,622.09
    -5.41 (-0.33%)
     

  • Jakarta Composite Index

    7,214.10
    +28.07 (+0.39%)
     

  • PSE Index

    6,607.22
    -26.44 (-0.40%)
     

Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

Alkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same period compares to $0.01 a year ago.

The reported revenue represents a surprise of -2.75% over the Zacks Consensus Estimate of $360.26 million. With the consensus EPS estimate being $0.59, the EPS surprise was -25.42%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Manufacturing and Royalty revenues: $116.83 million compared to the $122.54 million average estimate based on six analysts. The reported number represents a change of +60.4% year over year.

  • Revenues- Product sales, net: $233.54 million versus $240.07 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.

  • Revenues- Proprietary Sales- LYBALVI: $57 million versus the four-analyst average estimate of $57.01 million. The reported number represents a year-over-year change of +50%.

  • Revenues- Proprietary Sales- ARISTADA: $78.90 million versus the four-analyst average estimate of $81.37 million. The reported number represents a year-over-year change of -1.5%.

  • Revenues- Proprietary Sales- VIVITROL: $97.70 million versus $98.90 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1% change.

View all Key Company Metrics for Alkermes here>>>

Shares of Alkermes have returned -8.3% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alkermes plc (ALKS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research